The Urokinase Receptor (uPAR) as a “Trojan Horse” in Targeted Cancer Therapy: Challenges and Opportunities

One of the largest challenges to the implementation of precision oncology is identifying and validating selective tumor-driving targets to enhance the therapeutic efficacy while limiting off-target toxicity. In this context, the urokinase-type plasminogen activator receptor (uPAR) has progressively...

Full description

Saved in:
Bibliographic Details
Main Authors: Virginia Metrangolo, Michael Ploug, Lars H. Engelholm
Format: article
Language:EN
Published: MDPI AG 2021
Subjects:
Online Access:https://doaj.org/article/87757356f1974af4a545f9b7ae579182
Tags: Add Tag
No Tags, Be the first to tag this record!